Skip to main content
. 2020 Jun 5;74(2):175–182. doi: 10.1016/j.rec.2020.05.018

Table 3.

Association between ACEI/ARBs and hospital and ICU admissions

Events Admissions within the whole cohort ICU admissions within the admitted cohort
Univariate analysis
OR 95%CI P OR 95%CI P
 ACEI/ARBs 2.27 1.63-3.16 < .001 1.36 0.64-2.90 .427
 ACEI/ARBs ≥ 1 y 2.51 1.76-3.58 < .001 1.81 0.84-3.90 .127
 ACEI 2.01 1.24-3.28 .005 1.72 0.64-4.61 .281
 ACEI ≥ 1 y 1.89 1.10-3.27 .022 2.57 0.93-7.14 .070
 ARBs 2.09 1.42-3.08 < .001 0.99 0.40-2.43 .981
 ARBs ≥ 1 y 2.54 1.67-3.87 < .001 1.19 0.48-2.96 .703
Multivariate analysis*
OR 95%CI P OR 95%CI P
 ACEI/ARBs 0.85 0.45-1.64 .638 0.87 0.30-2.50 .798
 ACEI/ARBs ≥ 1 y 1.08 0.58-1.99 .808 1.13 0.37-3.42 .828
 ACEI 0.78 0.38-1.60 .505 0.97 0.22-4.16 .962
 ACEI ≥ 1 year 0.59 0.27-1.28 .182 1.23 0.27-5.60 .787
 ARBs 1.10 0.59-2.04 .757 0.84 0.25-2.87 .786
 ARBs ≥ 1 y 1.57 0.82-2.99 .173 1.02 0.28-3.64 .979
Propensity score matching
OR 95%CI P OR 95%CI P
 ACEI/ARBs 1.11 0.59-2.11 .744 1.00 0.22-4.45 1.000
 ACEI/ARBs ≥ 1 y 0.96 0.50-1.85 .909 1.50 0.34-6.70 .596
 ACEI 1.01 0.44-2.28 .988 0.65 0.07-5.97 .651
 ACEI ≥ 1 y 0.83 0.32-2.18 .709 1.05 0.01-1.06 .968
 ARBs 1.22 0.62-2.41 .572 1.16 0.25-5.47 .847
 ARBs ≥ 1 y 1.06 0.52-2.18 .871 1.54 0.32-7.33 .586

95%CI, 95% confidence interval; ACEI, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; ICU, intensive care unit; OR, odds ratio.

*

Whole cohort: adjustment for those variables with a P < .05 in the univariate analysis (days with symptoms, fever, arterial oxygen saturation < 95%, age, sex, health personnel, institutionalized, dependency status, dementia, hypertension, dyslipidemia, ventricular dysfunction, lung disease, previous cancer, hypothyroidism, antiplatelet therapy). ICU admitted cohort: adjustment for those variables with a P < .05 in the univariate analysis (arterial oxygen saturation < 95%, diabetes mellitus, hypoxemia, hypercapnia, lymphocytes, creatinine, elevated troponin, ferritin, C-reactive protein, interleukin-6) (table 2 of the supplementary data).